EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer.

ABSTRACT:

Objective

The poor prognosis and heterogeneity of stage III colon cancer (CC) suggest the need for more prognostic biomarkers. The tumor microenvironment (TME) plays a crucial role in tumor progression. We aimed to explore novel immune infiltration-associated molecules that serve as potential prognostic and therapeutic targets.

Methods

TME immune scores were calculated using "TMEscore" algorithm. Differentially expressed genes between the high and low TME immune score groups were identified and further investigated through a protein-protein interaction network and the Molecular Complex Detection algorithm. Cox regression, meta-analysis and immunohistochemistry were applied to identify genes significantly correlated with relapse-free survival (RFS). We estimated immune infilt

SUBMITTER: Wang X 

PROVIDER: S-EPMC9623419 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature